[1] R. K. Jain, “Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy,” Nature Medicine, vol. 7, no. 9, pp. 987–989, 2001.
[2] R. K. Jain, “Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy,” Science, vol. 307, no. 5706, pp. 58–62, 2005.
[3] R. Murata, Y. Nishimura, and M. Hiraoka, “An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma,” International 
[4] L. Bello, G. Carrabba, C. Giussani et al., “Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo,” Cancer Research, vol. 61, no. 20, pp. 7501–7506, 2001.
[5] J. Ma, S. Pulfer, S. Li, J. Chu, K. Reed, and J. M. Gallo, “Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470,” Cancer Research, vol. 61, no. 14, pp. 5491–5498, 2001.
[6] E. K. Rofstad, K. Henriksen, K. Galappathi, and B. Mathiesen, “Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts,” Cancer Research, vol. 63, no. 14, pp. 4055–4061, 2003.
[7] D. Zips, M. Krause, F. Hessel et al., “Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation,” Anticancer Research, vol. 23, no. 5, pp. 3869–3876, 2003.
[8] B. M. Fenton, S. F. Paoni, and I. Ding, “Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors,” Radiotherapy and Oncology, vol. 72, no. 2, pp. 221–230, 2004.
[9] J. Ma and D. J. Waxman, “Combination of antiangiogenesis with chemotherapy for more effective cancer treatment,” Molecular Cancer Therapeutics, vol. 7, no. 12, pp. 3670–3684, 2008.
[10] R. T. Tong, Y. Boucher, S. V. Kozin, F. Winkler, D. J. Hicklin, and R. K. Jain, “Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors,” Cancer Research, vol. 64, no. 11, pp. 3731–3736, 2004.
[11] C. G. Willett, Y. Boucher, E. Di Tomaso et al., “Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer,” Nature Medicine, vol. 10, no. 2, pp. 145–147, 2004.
[12] F. Winkler, S. V. Kozin, R. T. Tong et al., “Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases,” Cancer Cell, vol. 6, no. 6, pp. 553– 563, 2004.
[13] S. Kashiwagi, K. Tsukada, L. Xu et al., “Perivascular nitric oxide gradients normalize tumor vasculature,” Nature Medicine, vol. 14, no. 3, pp. 255–257, 2008.
[14] M. Franco, S. Man, L. Chen et al., “Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short- term and long-term impairment of vascular function and increase in tumor hypoxia,” Cancer Research, vol. 66, no. 7, pp. 3639–3648, 2006.
[15] A. Hormigo, P. H. Gutin, and S. Rafii, “Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers,” Cancer Cell, vol. 11, no. 1, pp. 6–8, 2007.
[16] T. T. Batchelor, A. G. Sorensen, E. di Tomaso et al., “AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients,” Cancer Cell, vol. 11, no. 1, pp. 83–95, 2007.
[17] C. W. Pugh and P. J. Ratcliffe, “Regulation of angiogenesis by hypoxia: role of the HIF system,” Nature Medicine, vol. 9, no. 6, pp. 677–684, 2003.
[18] R. G. Bristow and R. P. Hill, “Hypoxia and metabolism: hypoxia, DNA repair and genetic instability,” Nature Reviews Cancer, vol. 8, no. 3, pp. 180–192, 2008.
[19] S. Sengupta, D. Eavarone, I. Capila et al., “Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system,” Nature, vol. 436, no. 7050, pp. 568–572, 2005.
[20] F. Yuan, M. Leunig, S. K. Huang, D. A. Berk, D. Papahadjopou- los, and R. K. Jain, “Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft,” Cancer Research, vol. 54, no. 13, pp. 3352–3356, 1994.
[21] S. Sengupta and R. Sasisekharan, “Exploiting nanotechnology to target cancer,” British Journal of Cancer, vol. 96, no. 9, pp. 1315–1319, 2007.
[22] M. Kohandel, M. Kardar, M. Milosevic, and S. Sivaloganathan, “Dynamics of tumor growth and combination of antiangiogenic and cytotoxic therapies,” Physics in Medicine and Biology, vol. 52, no. 13, pp. 3665–3677, 2007.
[23] S. D. Perrault, C. Walkey, T. Jennings, H. C. Fischer, and W. C. W. Chan, “Mediating tumor targeting efficiency of nanoparticles through design,” Nano Letters, vol. 9, no. 5, pp. 1909–1915, 2009.
[24] R. K. Jain, “Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer,” Nature Reviews Cancer, vol. 8, no. 4, pp. 309–316, 2008.
[25] L. G. de Pillis, A. E. Radunskaya, and C. L. Wiseman, “A validated mathematical model of cell-mediated immune response to tumor growth,” Cancer Research, vol. 65, no. 17, pp. 7950–7958, 2005.